Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.
about
Cancer of the Pancreas: Molecular Pathways and Current Advancement in TreatmentHistone acetylation: novel target for the treatment of acute lymphoblastic leukemiaSignaling effectors underlying pathologic growth and remodeling of the heartKATs in cancer: functions and therapiesCreating a "Prosurvival Phenotype" Through Histone Deacetylase Inhibition: Past, Present, and FutureHistone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell ViabilityMolecular mechanisms of synaptic remodeling in alcoholismPreclinical evaluation of combined antineoplastic effect of DLC1 tumor suppressor protein and suberoylanilide hydroxamic acid on prostate cancer cellsThe anti-tumor effect of HDAC inhibition in a human pancreas cancer model is significantly improved by the simultaneous inhibition of cyclooxygenase 2Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation AssaysInhibition of histone deacetylase 6 restores innate immune cells in the bone marrow in a lethal septic model5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression in antiestrogen-resistant breast cancer cell lines.Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.Induction of sodium/iodide symporter (NIS) expression and radioiodine uptake in non-thyroid cancer cells.Histone deacetylase 1 reduces NO production in endothelial cells via lysine deacetylation of NO synthase 3.Regulation of CRADD-caspase 2 cascade by histone deacetylase 1 in gastric cancerSphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation.Histone deacetylase inhibition destabilizes the multi-potent state of uncommitted adipose-derived mesenchymal stromal cellsBlocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signalingSodium valproate alleviates neurodegeneration in SCA3/MJD via suppressing apoptosis and rescuing the hypoacetylation levels of histone H3 and H4HDAC6 deacetylase activity is required for hypoxia-induced invadopodia formation and cell invasion.Effects of SAHA on proliferation and apoptosis of hepatocellular carcinoma cells and hepatitis B virus replication.Ubiquitin B in cervical cancer: critical for the maintenance of cancer stem-like cell characters.Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.The effect of sulforaphane on histone deacetylase activity in keratinocytes: Differences between in vitro and in vivo analyses.HDAC inhibitors target HDAC5, upregulate microRNA-125a-5p, and induce apoptosis in breast cancer cellsHistone deacetylase 3 inhibits new tumor suppressor gene DTWD1 in gastric cancer.Potential non-oncological applications of histone deacetylase inhibitors.The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.Histone deacetylase inhibitors induce autophagy through FOXO1-dependent pathways.Phytochemical antioxidants modulate mammalian cellular epigenome: implications in health and disease.Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8.Silencing of Wnt5a during colon cancer metastasis involves histone modifications.Nanostructured lipid carriers loaded with tributyrin as an alternative to improve anticancer activity of all-trans retinoic acid.A trichostatin A expression signature identified by TempO-Seq targeted whole transcriptome profilingSelective inhibition of histone deacetylase 2 induces p53-dependent survivin downregulation through MDM2 proteasomal degradationHDAC inhibitors in experimental liver and kidney fibrosis.Regulation of intestinal serotonin transporter expression via epigenetic mechanisms: role of HDAC2.Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agentsHistone deacetylase inhibition: an important mechanism in the treatment of lymphoma.
P2860
Q26740619-BA7E2B09-81BA-40FC-9F65-B5A3C8385109Q26778780-A0D640E3-EDAF-4C53-9114-38188774E48CQ26825154-84953810-7041-451B-9734-D358CDB05A10Q26859355-6BB7CA3F-2B88-4DE0-83AC-37AD34EDF107Q26860240-B41C11E1-C8FE-49B4-BC26-60F7456FC2F3Q27679266-D047C639-039C-4C77-AE9E-D61A1B8DEBFBQ28080843-C15A678C-F0B0-4733-8A78-D82BC44BAFAAQ28383203-CBBA6E1F-9D29-40CD-BA6D-6E9E1B56C6DEQ28533258-98F6F58A-92ED-4D48-B439-5CD93118C664Q28550025-BB271096-2F48-4F66-BECB-8FEE0078F0B4Q30144009-04381746-A012-4414-98FE-14B6A66235DEQ33612962-C10B7692-5818-4738-B245-6715196AACA3Q33850064-F62E6FF2-FAE1-478E-9BA2-10C3E8FE787AQ34168357-2C873A30-DE7D-4CDB-AC20-E91FBCC286A3Q34296712-CD54F885-691A-4438-8A15-8C2C6A2032BDQ34420590-3ABDDB2C-8C87-4A90-B65D-02F99A29FF9BQ34428778-8C05E986-7A66-42B1-B48D-DCD246E01B0EQ34475885-BB52877C-BB48-4E0D-B611-B76EAD308D37Q34559028-994DBD6C-0E13-4333-8F89-AFAD4D6404D9Q34575681-F6DCA6CF-327C-4ADB-8CF4-2D12D0245960Q34584292-BC8F433D-5B48-46C3-9E09-25911294D07EQ34960201-28D11522-EDB4-4B08-BFAA-034083FC0015Q35075767-6AC8AB78-874F-489C-8B0A-701DA9F16095Q35214924-9B0FEF21-ACC4-4D6C-936D-160CDF5BCB4CQ35375018-70444383-B8AC-47FB-A687-7600DD4B1EAFQ35399130-E9D6EC12-56AB-42AF-9120-F1B821F0D332Q35402636-360B80D2-E3E6-4957-891C-574D44853934Q35485587-2F62E720-0229-42FC-9D41-D18CF4B647CDQ35846001-E447AA47-68C5-4778-BFF8-B9F637C7F6DDQ35852901-79763570-E605-490E-B0B7-590E9FEBEA67Q35965132-C6214EA5-1FF9-4D0B-8D75-10476F413938Q36019774-ECAC54A1-98A6-494A-96E2-436D2CCF1FDCQ36100968-A3B91037-3B6A-4277-9CE3-9BFE7E0AA8FBQ36253332-18AB7B67-0CA7-49F7-B046-A0EF5DBA90B8Q36380832-D91EC377-3C3D-4BFB-9CD1-34C046C35728Q36413516-87AE20C4-47E4-4C30-914F-24BB5A3AE904Q36588493-7AB21396-204F-4B16-90C2-402DEF21DD1BQ36593231-FB7B28B8-A5C1-430D-99A1-868B93CD686EQ36645808-6589DA11-03EB-4AE8-AA2E-73561AD494AFQ36814349-56598551-0802-48B0-9397-15E2D5424C57
P2860
Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Histone deacetylase inhibitors ...... l trials as anti-cancer drugs.
@ast
Histone deacetylase inhibitors ...... l trials as anti-cancer drugs.
@en
Histone deacetylase inhibitors ...... l trials as anti-cancer drugs.
@nl
type
label
Histone deacetylase inhibitors ...... l trials as anti-cancer drugs.
@ast
Histone deacetylase inhibitors ...... l trials as anti-cancer drugs.
@en
Histone deacetylase inhibitors ...... l trials as anti-cancer drugs.
@nl
prefLabel
Histone deacetylase inhibitors ...... l trials as anti-cancer drugs.
@ast
Histone deacetylase inhibitors ...... l trials as anti-cancer drugs.
@en
Histone deacetylase inhibitors ...... l trials as anti-cancer drugs.
@nl
P2860
P1476
Histone deacetylase inhibitors ...... al trials as anti-cancer drugs
@en
P2093
Hyun-Jung Kim
Suk-Chul Bae
P2860
P304
P407
P577
2010-12-26T00:00:00Z